Area of research
Surgery · Infectious Diseases
Research interest
Research interests include Helicobacter pylori-related gastroenterology studies, Clostridium difficile and Clostridium perfringens research, Microscopic Colitis, and Gastric Cancer Management and Outcomes.
Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study
Simultaneous application of oral and intravaginal probiotics for Helicobacter pylori and its antibiotic-therapy-induced vaginal dysbacteriosis
Dispersal history and bidirectional human-fish host switching of invasive, hypervirulent Streptococcus agalactiae sequence type 283
Colloidal bismuth pectin‐containing quadruple therapy as the first‐line treatment of <i>Helicobacter pylori</i> infection: A multicenter, randomized, double‐blind, non‐inferiority clinical trial
Comparison between percutaneous short-segment fixation and percutaneous vertebroplasty in treating Kummell’s disease: A minimum 2-year follow-up retrospective study
Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial
Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study
Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double‐blind, parallel‐controlled trial
Efficacy and safety of polaprezinc in the treatment of gastric ulcer: A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial
Chinese Consensus Report on Family-Based<i>Helicobacter pylori</i>Infection Control and Management (2021 Edition)
A retrospective study of the antibiotic-resistant phenotypes and genotypes of <i>Helicobacter pylori</i> strains in China.
PubMed 2021cited by 68position: middle
Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial
Long-term follow-up of <i>Helicobacter pylori</i> reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study
Vicenin‐2 inhibits the <i>Helicobacterium pylori</i> infection associated gastric carcinogenic events through modulation of PI3K/AKT and Nrf2 signaling in GES‐1 cells
Management of <i>Helicobacter pylori</i> infection by clinicians: A nationwide survey in a developing country
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for <i>Helicobacter pylori</i> infection: A multicenter randomized controlled trial in China